AARP weighs in on Merck case challenging Medicare drug negotiation [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
The organization is arguing that seniors would be harmed if the negotiations are struck down given the high cost of many drugs. In its brief , AARP noted that in 2022, ~9M Part D beneficiaries took at least one of those drugs and paid more than $3.4B in out-of-pocket cost just for the 10 drugs on the list. In addition, beneficiaries without financial help had average OOP costs as high as ~6.5K for these medications. In late August, CMS unveiled the first 10 drugs that would be subject to negotiated prices starting in 2026 Drugs on that list include: Eliquis, a blood thinner marketed by Bristol-Myers Squibb ( BMY ) and Pfizer ( PFE ); Jardiance, a diabetes therapy developed by Eli Lilly ( LLY ); and Imbruvica, a blood cancer therapy marketed by AbbVie ( ABBV ) and Johnson & Johnson ( JNJ ). Other targeted drugs include Merck's ( MRK ) diabetes med Januvia; AstraZeneca's ( AZN ) diabetes therapy Farxiga, Novartis' ( NVS ) cardiovascular drug Entresto, and JNJ's ( JNJ ) blood thin
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever [Yahoo! Finance]Yahoo! Finance
- Global Healthy Living Foundation Expands Access to Education and Clinical Trial Information for Spanish-Speaking Lupus Communities [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not [Seeking Alpha]Seeking Alpha
- Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound? [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 10/31/25 - Beat
BMY
Sec Filings
- 11/18/25 - Form 8-K
- 11/12/25 - Form CERT
- 11/10/25 - Form 8-A12B
- BMY's page on the SEC website